home.aspx
 
EVENTS

Medicinal and Pharmaceutical Chemistry
MEDICINAL AND PHARMACEUTICAL CHEMISTRY
December 16-17, 2019
Medicinal Chemistry is the science of design and chemical synthesis focusing mainly on small organic molecules and their development of pharmaceutical agents, or bio-active molecules (drugs). Pharmaceutical Chemistry is the same plus the science of pharmaceutical and biomedical analysis to the synth...

Drug Formulation & Analytical Techniques
DRUG FORMULATION & ANALYTICAL TECHNIQUES
December 16-17, 2019
Pharmaceutical formulation in pharmaceutics is the process in which various chemical substances including the vigorous drug are joined to produce a final medicinal product. Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally...

Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious and life-threatening diseases. Our medicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience, fibrosis and others.

RELATED NEWS


Looks like Amgen might not be buying Alexion Pharmaceuticals after all. Instead, its beefing up in psoriasis, where it already sells blockbuster TNF inhibitor Enbrel. Amgen Monday said it will take in Celgenes Otezla for 13.4 billion dollars in cash, a purchase that could help Bristol-Myers Squibb move along with its planned acquisition of Celgene for 74 billion dollars, per an agreement with U.S. antitrust authorities. The dollar amount easily dwarfs some recent biopharma deals for entire compa...

READ MORE

Hot cancer drugs have driven some of the biggest biopharma deals over the last decade, and thats certainly true of two of this years biggest transactions- Eli Lillys 8 billion dollars Loxo Oncology buy and Pfizers 11.4 billion dollars Array BioPharma acquisition. But the science behind those mergers speaks to a much larger trend in pharma M and A one that has spawned nearly 100 billion dollars in deals since 2010, according to a new analysis from SVB Leerink. Almost 40 Percent of the total value...

READ MORE

With Celgene making the big move under Bristol-Myers Squibbs umbrella, the drugmaker is looking to clear its books before the merger. Two antitrust settlements totaling more than 100 million dollars could help soothe BMS mind. Celgene will pay Mylan 62 million dollars to settle claims that it intentionally stifled generic competition for its blockbuster multiple myeloma med Revlimid and predecessor Thalomid. The Big Biotech refused to sell samples of the two drugs to generics makers, the lawsuit...

READ MORE

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo and its bringing in Bayer to help. The two companies, along with Bristol partner Ono Pharmaceutical, have joined forces in a clinical pact to test the immuno-oncology star alongside Bayers Stivarga in patients with microsatellite stable metastatic colorectal cancer, which represents about 95% of cases. The companies stayed tight-lipped on the collaboration’s terms, but they did note that t...

READ MORE

New Gilead CEO Daniel O Day has already replaced some key leaders at the company, but hes not stopping there with the executive overhaul. Wednesday, the Big Biotech said it would bid farewell to Gregg Alton, its chief patient officer, and Katie Watson, its EVP of human resources. In Watson’s place, Jyoti Mehra will step in to preside over Gilead’s worldwide HR function. Both departures end double-digit tenures at Gilead, where Alton and Watson have worked since 1999 and 2003, respect...

READ MORE

Antitrust regulators recently surprised industry watchers with the stipulation that Bristol-Myers Squibb sell Celgene's Otezla to win U.S. clearance for its $74 billion merger. But since then, as there’s no way around it, analysts have pulled out their calculators trying to put a dollar figure on the drug. Otezla could get Bristol about $5.4 billion, Bernstein analyst Ronny Gal said in a Monday note to clients. But his peers at Credit Suisse, Jefferies, RBC Capital and Wolfe Pharma are...
FIERCEPHARMA
READ MORE

Roche is heading for EU approval of Tecentriq as first-line therapy for triple-negative breast cancer (TNBC), ahead of its checkpoint inhibitor rivals. The Committee for Medicinal Products for Human Use (CHMP) backed the use of the PD-L1 inhibitor in patients with locally-advanced or metastatic TNBC that cannot be treated with surgery and who haven’t previously received chemotherapy. The EMA typically approves drugs a few weeks after a positive CHMP opinion. The new indication – whic...

READ MORE

Bristol-Myers Squibb has announced topline results from its CheckMate -459 trial evaluating Opdivo (nivolumab) in patients with unresectable hepatocellular carcinoma (HCC). The results show that the cancer drug failed to show superiority to Nexavar (sorafenib), and did not achieve statistical significance for its primary endpoint of overall survival. The news isn’t all negative, however, as a clear trend was demonstrated towards improvement in overall survival for patients treated with Opd...

READ MORE

With the Federal Trade Commission (FTC) sweating the details of Bristol-Myers Squibb and Celgene’s proposed $74 billion merger, all eyes were on the companies’ combined psoriasis portfolio, which regulators feared would corner the market. The feds found a solution: You can have your merger, but you don’t get to keep Celgene's blockbuster Otezla. Bristol-Myers will sell the psoriasis pill as part of a consent decree with the FTC intended to speed up its Celgene merger, the c...

READ MORE

Bristol-Myers Squibb’s Opdivo already boasts an FDA approval in liver cancer patients who have been treated with Bayer’s Nexavar. But its quest to jump into the front line just hit a snag. The BMS PD-1 drug failed to beat Nexavar at extending patients’ lives in a phase 3 study, the company acknowledged Monday. The Bayer drug has long been as the standard of care for patients with newly diagnosed hepatocellular carcinoma (HCC), competition-free in that indication until Eisai and...

READ MORE

EVENTS

International Conference on Metabolic Diseases and Liver Cancer
INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER
December 16-17, 2019
“INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER ’’ is organized in order to bring light and anticipate to the dark sides of human liver cancer and irregular human metabolic diseases which are prevailing worldwide. This conference is effective on all sides as it giv...

Drug Formulation & Analytical Techniques
DRUG FORMULATION & ANALYTICAL TECHNIQUES
December 16-17, 2019
Pharmaceutical formulation in pharmaceutics is the process in which various chemical substances including the vigorous drug are joined to produce a final medicinal product. Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally...